Overdose Data

​This webpage includes information about the Overdose Data Dashboard, emerging drug trends and reports. 


The Maryland Department of Health’s Interactive Overdose Dashboard is a tool for increasing access to timely overdose data and improving data-driven decision making for overdose prevention and response.

​Launched in July 2024 with extensive feedback from local and community partners, this dashboard is user-friendly and includes easy-to-understand visualization of overdose trends throughout the state.

Key Messages:

  • Based on preliminary data, fatal overdoses in Maryland have been on the decline in recent years. 
    • In 2025, there were 1,405 fatal overdoses in the state, the lowest level seen in the last 10 years. 
    • This is a 50 percent decrease from the state’s historic high of 2,800 in 2021.
  • While overdose death rates have shown signs of decline overall, disparities persist:
    • Overdose deaths among non-Hispanic Black men aged 55+ — the most impacted demographic group in terms of population size — fell to 98.6 per 100,000 individuals from 138.1 in 2024. 
    • ​Despite this decline, overdose rates for this group were still three times higher than the rate among white men in the same age group. 
  • ​Emergency Department (ED) visits for suspected non-fatal opioid overdoses have also seen a decline in recent years.
    • ​In 2025, there were 5,668 ED visits for suspected non-fatal opioid overdose, the lowest seen since 2023 — a 41% decrease from the state’s historic high of 9,633 ED visits in 2021. 
  • ​Similar to trends in fatal overdose, disparities in non-fatal overdose burden by sex, race, ethnicity and age persist: 
    • ED visits for non-fatal opioid overdose were highest among non-Hispanic Black men aged 55+ compared to all other sex, race, ethnicity and age groups. 
    • In 2025, the rate of ED visits in this group fell to 471.7 per 100,000 individuals from 670.2 in 2024. Yet, the 2025 ED visit rate for this group was 7x higher than the rate among non-Hispanic White men in the same age group. 

Emerging Drugs

Reports